Pillay-Smiley, N.; Leach, J.; Lane, A.; Hummel, T.; Fangusaro, J.; de Blank, P.
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. Cancers 2023, 15, 2109.
https://doi.org/10.3390/cancers15072109
AMA Style
Pillay-Smiley N, Leach J, Lane A, Hummel T, Fangusaro J, de Blank P.
Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. Cancers. 2023; 15(7):2109.
https://doi.org/10.3390/cancers15072109
Chicago/Turabian Style
Pillay-Smiley, Natasha, James Leach, Adam Lane, Trent Hummel, Jason Fangusaro, and Peter de Blank.
2023. "Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B" Cancers 15, no. 7: 2109.
https://doi.org/10.3390/cancers15072109
APA Style
Pillay-Smiley, N., Leach, J., Lane, A., Hummel, T., Fangusaro, J., & de Blank, P.
(2023). Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. Cancers, 15(7), 2109.
https://doi.org/10.3390/cancers15072109
